MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1007/s00277-019-03767-y

Медицинская библиотека · Annals of hematology · 2019

Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline.

Crugnola Monica, Castagnetti Fausto, Breccia Massimo, Ferrero Dario, Trawinska Malgorzata Monika, Abruzzese Elisabetta, Annunziata Mario, Stagno Fabio, Tiribelli Mario, Binotto Gianni, Bonifacio Massimiliano, Fava Carmen, Iurlo Alessandra, Bucelli Cristina, Mansueto Giovanna, Gozzini Antonella, Falzetti Franca, Montefusco Enrico, Crisà Elena, Gugliotta Gabriele, Russo Sabina, Cedrone Michele, RussoRossi Antonella, Pregno Patrizia, Isidori Alessandro, Mauro Endri, Atelda Romano, Giglio Gianfranco, Celesti Francesca, Sorà Federica, Storti Sergio, D'Addosio Adam, Galimberti Sara, Orlandi Ester, Calistri Elisabetta, Bocchia Monica, Cavazzini Francesco, Rege Cambrin Giovanna, Orofino Nicola, Luciano Luigiana, Sgherza Nicola, Rosti Gianantonio, Latagliata Roberto, Capodanno Isabella

Клиническое исследованиеСтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

Very elderly (> 75 years) chronic myeloid leukaemia (CML) patients at diagnosis are sometimes treated with different doses of imatinib (IM) based on concomitant diseases and physicians' judgement. However, data on long-term follow-up of these patients are still lacking. To investigate treatment response and outcome, we retrospectively revised an Italian database of 263 very elderly CML patients receiving IM from the time of diagnosis. Median age at diagnosis was 78.5 years and 56% of patients had 2 or 3 comorbidities. A complete haematological and cytogenetic response were achieved in 244 (92.8%) and 184 (69.9%) patients, respectively. In 148 cases (56.2%), a major molecular response was observed, which was deep in 63 cases (24%). A blastic phase occurred in 11 patients (4.2%). After a median follow-up of 45.0 months, 93 patients have died (9 from disease progression) and 104 (39.5%) are still in treatment with IM. Incidence of grades 3-4 haematological and non-haematological toxicity was similar to those reported in younger patients. Five-year event-free survival was 54.5% and 45.2% in patients ≤ 80 years and > 80 years, respectively (p = 0.098). Five years OS was 75.7% and 61.6% in patients ≤80 years and > 80 years, respectively (p = 0.003). These findings show that IM plays an important role in frontline treatment of very elderly CML patients without increased toxicity and any effort to treat these patients with standard doses should be made in order to achieve responses as in younger subjects.

Для цитирования: Crugnola Monica, Castagnetti Fausto, Breccia Massimo, Ferrero Dario, Trawinska Malgorzata Monika, Abruzzese Elisabetta, Annunziata Mario, Stagno Fabio, Tiribelli Mario, Binotto Gianni, Bonifacio Massimiliano, Fava Carmen, Iurlo Alessandra, Bucelli Cristina, Mansueto Giovanna, Gozzini Antonella, Falzetti Franca, Montefusco Enrico, Crisà Elena, Gugliotta Gabriele, Russo Sabina, Cedrone Michele, RussoRossi Antonella, Pregno Patrizia, Isidori Alessandro, Mauro Endri, Atelda Romano, Giglio Gianfranco, Celesti Francesca, Sorà Federica, Storti Sergio, D'Addosio Adam, Galimberti Sara, Orlandi Ester, Calistri Elisabetta, Bocchia Monica, Cavazzini Francesco, Rege Cambrin Giovanna, Orofino Nicola, Luciano Luigiana, Sgherza Nicola, Rosti Gianantonio, Latagliata Roberto, Capodanno Isabella. Outcome of very elderly chronic myeloid leukaemia patients treated with imatinib frontline.. Annals of hematology. 2019. DOI: 10.1007/s00277-019-03767-y.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.